nach oben

Clinical Orthopaedics and Related Research®

Erschienen in:

01.08.2011 | Symposium: Bone Quality: From Bench to Bedside

Diseases Affecting Bone Quality: Beyond Osteoporosis

verfasst von: Aasis Unnanuntana, MD, Brian J. Rebolledo, BA, M. Michael Khair, MD, Edward F. DiCarlo, MD, Joseph M. Lane, MD

Erschienen in: Clinical Orthopaedics and Related Research® | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Bone quantity, quality, and turnover contribute to whole bone strength. Although bone mineral density, or bone quantity, is associated with increased fracture risk, less is known about bone quality. Various conditions, including disorders of mineral homeostasis, disorders in bone remodeling, collagen disorders, and drugs, affect bone quality.

Questions/purposes

The objectives of this review are to (1) identify the conditions and diseases that could adversely affect bone quality besides osteoporosis, and (2) evaluate how these conditions influence bone quality.

Methods

We searched PubMed using the keywords “causes” combined with “secondary osteoporosis” or “fragility fracture.” After identifying 20 disorders/conditions, we subsequently searched each condition to evaluate its effect on bone quality.

Results

Many disorders or conditions have an effect on bone metabolism, leading to fragility fractures. These disorders include abnormalities that disrupt mineral homeostasis, lead to an alteration of the mineralization process, and ultimately reduce bone strength. The balance between bone formation and resorption is also essential to prevent microdamage accumulation and maintain proper material and structural integrity of the bone. As a result, diseases that alter the bone turnover process lead to a reduction of bone strength. Because Type I collagen is the most abundant protein found in bone, defects in Type I collagen can result in alterations of material property, ultimately leading to fragility fractures. Additionally, some medications can adversely affect bone.

Conclusions

Recognizing these conditions and diseases and understanding their etiology and pathogenesis is crucial for patient care and maintaining overall bone health.

Abbasi AA, Rudman D, Wilson CR, Drinka PJ, Basu SN, Mattson DE, Richardson TJ. Observations on nursing home residents with a history of hip fracture. Am J Med Sci. 1995;310:229–234.PubMed

Alman BA, Goldberg MJ. Metabolic and endocrine abnormalities. In: Lovell WW, Winter RB, Morrissy RT, Weinstein SL. eds. Lovell and Winter’s Pediatric Orthopaedics. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2006:167–203.

Amir E, Simmons CE, Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M. A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases. Cancer. 2010;116:284–291.PubMed

Barnes AM, Carter EM, Cabral WA, Weis M, Chang W, Makareeva E, Leikin S, Rotimi CN, Eyre DR, Raggio CL, Marini JC. Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. N Engl J Med. 2010;362:521–528.PubMed

Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;6:2635–2643.

Basel D, Steiner RD. Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition. Genet Med. 2009;6:375–385.

Beighton P, Horan F. Orthopaedic aspects of the Ehlers-Danlos syndrome. J Bone Joint Surg Br. 1969;51:444–453.PubMed

Bilezikian JP, Potts JT Jr. Asymptomatic primary hyperparathyroidism: new issues and new questions—bridging the past with the future. J Bone Miner Res. 2002:N57–67.

Bouxsein ML. Determinants of skeletal fragility. Best Pract Res Clin Rheumatol. 2005;6:897–911.

10.

Brown SA, Guise TA. Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr. 2009;19:47–60.PubMed

11.

Burstein AH, Zika JM, Heiple KG, Klein L. Contribution of collagen and mineral to the elastic-plastic properties of bone. J Bone Joint Surg Am. 1975;57:956–961.PubMed

12.

Bushinsky DA. Bone disease in moderate renal failure: cause, nature and prevention. Annu Rev Med. 1997:167–176.

13.

Callewaert B, Malfait F, Loeys B, De Paepe A. Ehlers-Danlos syndromes and Marfan syndrome. Best Pract Res Clin Rheumatol. 2008;1:165–189.

14.

Calve S, Lytle IF, Grosh K, Brown DL, Arruda EM. Implantation increases tensile strength and collagen content of self-assembled tendon constructs. J Appl Physiol. 2010;108:875–881.PubMed

15.

Caplan GA, Scane AC, Francis RM. Pathogenesis of vertebral crush fractures in women. J R Soc Med. 1994;87:200–202.PubMed

16.

Carbone L, Tylavsky FA, Bush AJ, Koo W, Orwoll E, Cheng S. Bone density in Ehlers-Danlos syndrome. Osteoporos Int. 2000;5:388–392.

17.

Cheung MS, Glorieux FH. Osteogenesis imperfecta: update on presentation and management. Rev Endocr Metab Disord. 2008;2:153–160.

18.

Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T, deVernejoul MC, Van Hul W. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet. 2001;25:2861–2867.

19.

Clemetson CA. Barlow’s disease. Med Hypotheses. 2002;1:52–56.

20.

Coelho PC, Santos RA, Gomes JA. Osteoporosis and Ehlers-Danlos syndrome. Ann Rheum Dis. 1994;3:212–213.

21.

Conney AH. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev. 1967;19:317–366.PubMed

22.

Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;4:281–289.

23.

Currey JD. The relationship between the stiffness and the mineral content of bone. J Biomech. 1969;4:477–480.

24.

Currey JD. Strain rate and mineral content in fracture models of bone. J Orthop Res. 1988;1:32–38.

25.

Dent CE, Richens A, Rowe DJ, Stamp TC. Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br Med J. 1970;5727:69–72.

26.

Di Munno O, Delle Sedie A, Rossini M, Adami S. Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:137–144.PubMed

27.

Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int. 2003;5:423–432.

28.

Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, ATAC Trialists’ group. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230). J Bone Miner Res. 2006;8:1215–1223.

29.

Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med. 2008;14:1474–1482.

30.

Eichelbaum M, Ekbom K, Bertilsson L, Ringberger VA, Rane A. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol. 1975;5:337–341.

31.

Einhorn TA. Metabolic bone disease. In: Einhorn TA, Buckwalter JA, O’Keefe RJ, American Academy of Orthopaedic Surgeons, eds. Orthopaedic Basic Science: Foundations of Clinical Practice. 3rd ed. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2007:415–426.

32.

Epstein S, Schneider AE. Drug and hormone effect on vitamin D metabolism. In: Feldman D, Glorieux FH, Pike JW, eds. Vitamin D. 2nd ed. San Diego: Elseiver Academic Press; 2005:1291

33.

Erben RG, Eberle J, Stahr K, Goldberg M. Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometric study. J Bone Miner Res. 2000;6:1085–1098.

34.

Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther. 2005;1:1–11.

35.

Fiore CE, Pennisi P, Ciffo F, Scebba C, Amico A, Di Fazzio S. Immobilization-dependent bone collagen breakdown appears to increase with time: evidence for a lack of new bone equilibrium in response to reduced load during prolonged bed rest. Horm Metab Res. 1999;1:31–36.

36.

Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002;5:453–468.

37.

Francis RM, Peacock M, Aaron JE, Selby PL, Taylor GA, Thompson J, Marshall DH, Horsman A. Osteoporosis in hypogonadal men: role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption, and low bone formation. Bone. 1986;4:261–268.

38.

Fraser WD. Hyperparathyroidism. Lancet. 2009;9684:145–158.

39.

Frick KK, Bushinsky DA. Metabolic acidosis stimulates RANKL RNA expression in bone through a cyclo-oxygenase-dependent mechanism. J Bone Miner Res. 2003;7:1317–1325.

40.

Giampietro PF, Peterson MG, Schneider R, Davis JG, Burke SW, Boachie-Adjei O, Mueller CM, Raggio CL. Bone mineral density determinations by dual-energy x-ray absorptiometry in the management of patients with Marfan syndrome—some factors which affect the measurement. HSS J. 2007;1:89–92.

41.

Giampietro PF, Raggio C, Davis JG. Marfan syndrome: orthopedic and genetic review. Curr Opin Pediatr. 2002;1:35–41.

42.

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlbock M, Jakesz R, Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9:840–849.PubMed

43.

Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89:349–353.PubMed

44.

Goodman SB, Jiranek W, Petrow E, Yasko AW. The effects of medications on bone. J Am Acad Orthop Surg. 2007;15:450–460.PubMed

45.

Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the women’s health initiative. Arch Intern Med. 2010;9:765–771.

46.

Graziani G, Como G, Badalamenti S, Finazzi S, Malesci A, Gallieni M, Brancaccio D, Ponticelli C. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant. 1995;10:1376–1380.PubMed

47.

Hardy P, Sechet A, Hottelart C, Oprisiu R, Abighanem O, Said S, Rasombololona M, Brazier M, Moriniere P, Achard JM, Pruna A, Fournier A. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs. 1998;7:569–573.

48.

Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr. 2003;22:142–146.PubMed

49.

Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am. 2004;2:331–352.

50.

Hmamouchi I, Renard E, Thomas E, Missounga L, Blotman F, Cyteval C. Fracture from brown tumor due to parathyroid adenoma secondary to vitamin D deficiency. J Radiol. 2008;9:1109–1112.

51.

Hodgson SF. Corticosteroid-induced osteoporosis. Endocrinol Metab Clin North Am. 1990;19:95–111.PubMed

52.

Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 2005;135:317–22.PubMed

53.

Hollis BW, Wagner CL. Normal serum vitamin D levels. N Engl J Med. 2005;5:515–516.

54.

Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res. 2007;10:1492–1501.

55.

Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A, National Osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int. 2008;10:1395–1408.

56.

Kaplan FS, August CS, Dalinka MK, Karp J, Fallon MD, Haddad JG. Bone densitometry observations of osteopetrosis in response to bone marrow transplantation. Clin Orthop Relat Res. 1993;294:79–84.PubMed

57.

Key LL Jr, Rodriguiz RM, Willi SM, Wright NM, Hatcher HC, Eyre DR, Cure JK, Griffin PP, Ries WL. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med. 1995;24:1594–1599.

58.

Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest. 2006;8:2152–2160.

59.

Kuurila K, Grenman R, Johansson R, Kaitila I. Hearing loss in children with osteogenesis imperfecta. Eur J Pediatr. 2000;7:515–519.

60.

Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;2:224–231.

61.

Landa J, Margolis N, Di Cesare P. Orthopaedic management of the patient with osteopetrosis. J Am Acad Orthop Surg. 2007;15:654–662.PubMed

62.

Landis WJ, Hodgens KJ, Song MJ, Arena J, Kiyonaga S, Marko M, Owen C, McEwen BF. Mineralization of collagen may occur on fibril surfaces: evidence from conventional and high-voltage electron microscopy and three-dimensional imaging. J Struct Biol. 1996;1:24–35.

63.

Lanyon LE. Using functional loading to influence bone mass and architecture: objectives, mechanisms, and relationship with estrogen of the mechanically adaptive process in bone. Bone. 1996;18(Suppl):37S–43S.PubMed

64.

Leidig-Bruckner G, Ziegler R. Diabetes mellitus a risk for osteoporosis? Exp Clin Endocrinol Diabetes. 2001;109(Suppl 2):S493–S514.PubMed

65.

Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;8:1353–1362.

66.

Le Parc JM, Plantin P, Jondeau G, Goldschild M, Albert M, Boileau C. Bone mineral density in sixty adult patients with Marfan syndrome. Osteoporos Int. 1999;6:475–479.

67.

Lochmuller EM, Zeller JB, Kaiser D, Eckstein F, Landgraf J, Putz R, Steldinger R. Correlation of femoral and lumbar DXA and calcaneal ultrasound, measured in situ with intact soft tissues, with the in vitro failure loads of the proximal femur. Osteoporos Int. 1998;8:591–598.PubMed

68.

Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161:1219–1222.PubMed

69.

Malabanan AO, Holick MF. Vitamin D and bone health in postmenopausal women. J Womens Health (Larchmt). 2003;2:151–156.

70.

Mankin HJ. Metabolic bone disease. Instr Course Lect. 1995;44:3–29.PubMed

71.

Mankin HJ. Osteopetrosis. In: Mankin HJ, ed. Pathophysiology of Orthopaedic Diseases. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2006:123–129.

72.

Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD, Milgrom S, Hyland JC, Korkko J, Prockop DJ, De Paepe A, Coucke P, Symoens S, Glorieux FH, Roughley PJ, Lund AM, Kuurila-Svahn K, Hartikka H, Cohn DH, Krakow D, Mottes M, Schwarze U, Chen D, Yang K, Kuslich C, Troendle J, Dalgleish R, Byers PH. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat. 2007;3:209–221.

73.

Mazess RB, Whedon GD. Immobilization and bone. Calcif Tissue Int. 1983;3:265–267.

74.

Natoli RM, Skaalure S, Bijlani S, Chen KX, Hu J, Athanasiou KA. Intracellular Na(+) and Ca(2 +) modulation increases the tensile properties of developing engineered articular cartilage. Arthritis Rheum. 2010;62:1097–1107.PubMed

75.

O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;7:778–781.

76.

Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–1301.PubMed

77.

Peris P, Guanabens N, Monegal A, Suris X, Alvarez L, Martinez de Osaba MJ, Hernandez MV, Munoz-Gomez J. Aetiology and presenting symptoms in male osteoporosis. Br J Rheumatol. 1995;10:936–941.

78.

Peterkofsky B. Ascorbate requirement for hydroxylation and secretion of procollagen: relationship to inhibition of collagen synthesis in scurvy. Am J Clin Nutr. 1991;54(Suppl):1135S–1140S.PubMed

79.

Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18:1570–1593.PubMed

80.

Rajakumar K. Infantile scurvy: a historical perspective. Pediatrics. 2001;4:E76.

81.

Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget’s disease of bone. Lancet. 2008;9633:155–163.

82.

Recker RR. Calcium absorption and achlorhydria. N Engl J Med. 1985;313:70–73.PubMed

83.

Reddy GK, Stehno-Bittel L, Hamade S, Enwemeka CS. The biomechanical integrity of bone in experimental diabetes. Diabetes Res Clin Pract. 2001;1:1–8.

84.

Richens A, Rowe DJ. Disturbance of calcium metabolism by anticonvulsant drugs. Br Med J. 1970;5727:73–76.

85.

Rosen CJ, Adler RA. Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab. 1992;6:1531–1534.

86.

Sahni S, Hannan MT, Gagnon D, Blumberg J, Cupples LA, Kiel DP, Tucker KL. Protective effect of total and supplemental vitamin C intake on the risk of hip fracture–a 17-year follow-up from the Framingham Osteoporosis Study. Osteoporos Int. 2009;11:1853–1861.

87.

Scane AC, Sutcliffe AM, Francis RM. Osteoporosis in men. Baillieres Clin Rheumatol. 1993;3:589–601.

88.

Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JP, Pols HA. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone. 2004;1:195–202.

89.

Schultheis L. The mechanical control system of bone in weightless spaceflight and in aging. Exp Gerontol. 1991;26:203–214.PubMed

90.

Sherrard DJ, Hercz G, Pei Y, Segre G. The aplastic form of renal osteodystrophy. Nephrol Dial Transplant. 1996;11(Suppl 3):29–31.PubMed

91.

Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;2:101–116.

92.

Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Feldman F, Seldin D, Jacobs TP, Siris ES, Cafferty M, Parisien MV. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res. 1989;3:283–291.

93.

Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;10:1108–1112.

94.

Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res. 2005;10:1813–1819.

95.

Spasovski G. Low turn-over bone disease in patients with chronic renal disease. Med Pregl. 2007;60(Suppl 2):21–24.PubMed

96.

Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, Fahrleitner-Pammer A, Petto H, Westmore M, Michalsky D, Sato M, Dobnig H. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone. 2007;3:378–385.

97.

Taxel P, Kenny A. Differential diagnosis and secondary causes of osteoporosis. Clin Cornerstone. 2000;6:11–21.

98.

Tejwani NC, Schachter AK, Immerman I, Achan P. Renal osteodystrophy. J Am Acad Orthop Surg. 2006;14:303–311.PubMed

99.

Turner CH. Bone strength: current concepts. Ann N Y Acad Sci. 2006;1068:429–446.PubMed

100.

van der Rest M, Garrone R. Collagen family of proteins. FASEB J. 1991;5:2814–2823.PubMed

101.

Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev. 2004;3:389–425.

102.

Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;2:76–83.

103.

Vico L, Chappard D, Alexandre C, Palle S, Minaire P, Riffat G, Morukov B, Rakhmanov S. Effects of a 120 day period of bed-rest on bone mass and bone cell activities in man: attempts at countermeasure. Bone Miner. 1987;2:383–394.PubMed

104.

Vieth R. Vitamin D toxicity, policy, and science. J Bone Miner Res. 2007;22(Suppl 2):V64–V68.PubMed

105.

Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, Johnson M, Kocisko M, Evans WE, Foroud T, Econs MJ. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res. 2003;8:1513–1518.

106.

Weng MY, Lane NE. Medication-induced osteoporosis. Curr Osteoporos Rep. 2007;4:139–145.

107.

Wermers RA, Tiegs RD, Atkinson EJ, Achenbach SJ, Melton LJ 3rd. Morbidity and mortality associated with Paget’s disease of bone: a population-based study. J Bone Miner Res. 2008;6:819–825.

108.

Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;24:2947–2953.

109.

Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 2008;6:1674–1686.

110.

Zehnder Y, Luthi M, Michel D, Knecht H, Perrelet R, Neto I, Kraenzlin M, Zach G, Lippuner K. Long-term changes in bone metabolism, bone mineral density, quantitative ultrasound parameters, and fracture incidence after spinal cord injury: a cross-sectional observational study in 100 paraplegic men. Osteoporos Int. 2004;3:180–189.

Titel: Diseases Affecting Bone Quality: Beyond Osteoporosis
verfasst von: Aasis Unnanuntana, MD
Brian J. Rebolledo, BA
M. Michael Khair, MD
Edward F. DiCarlo, MD
Joseph M. Lane, MD
Publikationsdatum: 01.08.2011
Verlag: Springer-Verlag
Erschienen in: Clinical Orthopaedics and Related Research® / Ausgabe 8/2011
Print ISSN: 0009-921X
Elektronische ISSN: 1528-1132
DOI: https://doi.org/10.1007/s11999-010-1694-9

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Questions/purposes

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2011

Simultaneous Nailing of Skeletal Metastases: Is the Mortality Really that High?

Does Texturing of UHMWPE Increase Strength and Toughness?: A Pilot Study

Raman Assessment of Bone Quality

History and Systematic Review of Wear and Osteolysis Outcomes for First-generation Highly Crosslinked Polyethylene

Cartilage-mimicking, High-density Brush Structure Improves Wear Resistance of Crosslinked Polyethylene: A Pilot Study